Given the fact that during a biofilm-associated infection, the first primary interface 27 between the host and the bacteria is the self-produced extracellular matrix, in this study, 28
we have analysed the potential of extracellular proteins found in the biofilm matrix to 29 induce a protective immune response against S. aureus infections. By using proteomic 30 approaches we characterized the exoproteomes of exopolysaccharide-based and 31
protein-based biofilm matrices produced by two clinical S. aureus strains. Remarkably, 32 results showed that independently of the nature of the biofilm matrix, a common core 33 of secreted proteins is contained in both types of exoproteomes. Ten µg RNAs were reverse transcribed using SuperScript II reverse transcriptase 211 (Invitrogen Life Technologies). cDNA was digested by DNase I (PIERCE) in 10X 212
DNAse I buffer (USB-Affymetrix) and the size of digestion products was analyzed in 213 the Agilent Bioanalyser 2100 using RNA Nano LabChips to ensure that the 214 fragmentation resulted in a majority of products in the range of 50 to 200 base-pairs. 215
The fragmented cDNA were then biotinylated using terminal deoxynucleotidyl 216 transferase (Promega) and the GeneChip DNA labeling reagent (Affymetrix) following 217 the manufacturer's recommendations. Biotinylated cDNA (5 microgram per array) were 218 hybridized to custom S. aureus tiling microarrays designed as described (43) exoprotein extract used for immunization consisted of the exoproteins purified from the 233 biofilm matrix produced by S. aureus 15981 strain and was referred as BME. Five-234 week-old female CD1 mice were injected intradermally with 10 µg of BME diluted in 235 adjuvant (Sigma Adjuvant System®). The control group was treated with PBS and 236 adjuvant. Two weeks later, the vaccinated group received a booster dose of 5 µg of 237 BME, while the control group received PBS and adjuvant. Mice were bled via the 238 retroorbital venous plexus on day 0 (pre-immune serum) and 21 days after the first 239 vaccination (immune serum). Both serum samples were analyzed by ELISA and 240
Western Blot for determination of antibody responses against the BME. 241
242
Detection of antibodies in the sera. 243
Serum IgG and IgM expression against BME were quantified by coating 96-well 244 ELISA plates (Nunc Maxisorp, Millipore) with 100 µl/well of a 0.1 µg ml -1 BME in 245 carbonate buffer (0.5 M; pH 9.4). Plates were incubated at 4ºC overnight. After 246 incubation, wells were then washed three times with PBS containing 0.1% Tween-20 247 (PBS-T; pH 7.4) and blocked with blocking buffer (5% nonfat dried milk powder in 248 PBS-T) at room temperature for 1h. After washing three times with PBS-T, 100 µl of 249 pre-immune (negative-control) and immune serum diluted 1:100 in PBS were added to 250 each well and incubated at 37ºC for 2 h. After incubation, wells were washed three 251 times with PBS-T and 100 µl of HRP-conjugated goat anti-mouse IgG and IgM 252 (Thermo Scientific) were added to each well. The plates were incubated for 1 h at 37°C 253 and then washed three times. One hundred µl of ABTS solution (diammonium 2,2'-254 azinobis[3-ethyl-2,3-dihydrobenzothiazole-6-sulphonate; Millipore) were added to each 255 well and the absorbance at 405nm was determined on an ELISA reader. Results were 256 reported as the OD 405 of immune serum/OD 405 of the control serum (T/C). 257
Immune response was also determined by Western blot. For that, 5 µg of the BME or a 258 planktonic culture exoproteins extract were resolved using SDS-polyacrylamide gel 259 electrophoresis, transferred to a nitrocellulose membrane and incubated with blocking 260 buffer. Then, the membrane was exposed to pre-immune (negative-control) and 261 immune serum at 4ºC overnight. After washing five times with washing buffer (PBS-T 262 0.1%), the membrane was incubated with goat anti-mouse IgG and IgM (H+L) 263 secondary antibody HRP conjugate and proteins were detected using SuperSignal® 264
WestPico Chemiluminescent Substrate (Thermo Scientific). 265
266

Opsonophagocytic assays. 267
Opsonophagocytosis and killing assay has been previously described in (45). Briefly, 1 268 ml of a planktonic culture of strain S. aureus 132 grown overnight was pelleted for 5 269 min at 12,000 g at 4°C, washed twice with PBS, and subsequently diluted to an OD 600 270 of 0.5. Bacteria were pre-incubated with 1% or 10% of immune serum, pre-immune 271 serum or PBS for 1 h at 4ºC. The opsonophagocytosis assay was performed with fresh 272 blood obtained from human healthy volunteers. Fresh whole blood from three 273 volunteers was collected and mixed in tubes containing the anticoagulant heparin and 274 then aliquoted into 1.5-ml microcentrifuge tubes (0.5 ml/tube). After pre-incubation, 10 275 µl of bacterial suspensions were added to the 1.5-ml microcentrifuge tubes containing 276 0.5 ml of fresh blood. Tubes were incubated at room temperature with gentle rocking 277 and, after 30 min, samples were serially diluted and plated onto TSA plates to 278 determine the number of surviving CFU. 
infection. 308
The vaccination protocol was performed as described in the "Immunization Studies" 309 section using BME, PLKE or 10 8 heat-killed bacteria emulsified in adjuvant for 310 immunization. Groups of 6 CD1 mice were used. One week after the second 311 immunization, a model of mesh-associated biofilm infection was performed as 312 previously described (46) with the following modifications. Prior to surgical procedure, 313 0.5x0.5cm polypropylene meshes (Prolene®) were incubated with 0.5 ml of a 1:100 314 overnight dilution of a culture of the biofilm forming strain S. aureus 132 for 1 hour 315
and 15 minutes at 37ºC with shaking. To calculate the initial inoculum, duplicate 316 meshes were placed in 1 ml of PBS and vigorously vortexed. Samples were serially 317 diluted and plated onto TSA plates for enumeration of viable staphylococci. Control 318 and vaccinated CD1 mice were anesthetized by intraperitoneal injection of a 319 ketamine/xylazine mixture. After abdominal epilation and antisepsis of the operative 320 field, the animals were operated. An incision of 1.5 cm in the skin was performed with 321 displacement of the subcutaneous space and opening the peritoneal cavity. Then, a 322 mesh, coated with 10 4 CFU of S. aureus strain 132, was fixed at the abdominal wall 323 with one anchor point. Finally, the peritoneal cavity was closed by suture with 6/0 324
Monosyn®. The animals were put in a warm environment and when awake, they were 325 put back in their cages. After 5 days, all animals were sacrificed. Mesh and surrounding 326 tissue were extracted and placed in 1 ml of PBS and vigorously vortexed. 
RESULTS
336
Identification of the S. aureus biofilm matrix exoproteome. 337
In order to isolate and identify the exoproteins present within the biofilm matrix, the 338 biofilm formed by the clinical strain S. aureus 15981 grown in TSB-gluc was isolated 339 (38). This strain forms a PNAG dependent biofilm when grown under the conditions 340 tested. Exoproteins present within the PNAG-mediated biofilm matrix of 3 independent 341 samples were purified as described in the materials and methods section. Proteins from 342 these extracts were precipitated and then separated by 1-D SDS-PAGE followed by 343 trypsin digestion and identified by 2DnLC-MS/MS. Only proteins identified in at least 344 two of the three samples were considered for further analysis. Thus, a total of 33 345 extracellular proteins were detected with a MASCOT score higher than 50 (Table 2) . With the aim of extending the biofilm matrix exoproteome analysis to other S. aureus 366 strains we used strain 132, which is an MRSA clinical isolate able to alternate between 367 a PNAG-independent biofilm matrix mediated by the Fibronectin Binding Proteins 368 (FnBPs) and an exopolysaccharidic PNAG-mediated biofilm depending of whether it is 369 cultured under TSB-gluc or TSB-NaCl growing conditions, respectively (23). S. aureus 370 132 was incubated in microfermentors under these two different conditions that 371 allowed the formation of the two biofilm matrices and subsequently, these were 372 isolated for matrix exoproteins identification. Analysis of the PNAG-mediated biofilm 373 matrix revealed the presence of 24 proteins, 17 of which (71%) had been previously 374 identified in the S. aureus 15981 strain exoproteome. On the other hand, analysis of the 375 FnBPs-mediated biofilm matrix led to the identification of 19 proteins, being nearly 376 half of them also present in the exoproteome of the PNAG-mediated matrix, and the 377 other half in the S. aureus 15981 strain exoproteome. When we considered the biofilm 378 matrices formed by S. aureus 132 under these two experimental conditions as a unit, 379 results showed that almost 80% of the matrix exoproteins were included into the 380 biofilm matrix exoproteome of the S. aureus 15981 strain. 381
In conclusion, we identified the PNAG-dependent and FnBPs-dependent biofilm matrix 382 exoproteomes of a methicillin resistant S. aureus isolate and also the PNAG-dependent 383 exoproteome of a methicillin sensitive clinical strain. The results indicated that 384 independently of the nature of the biofilm matrix, a common core of secreted proteins 385 is contained in both types of exoproteomes. The biofilm matrix exoprotein extract used 386 for the rest of the study consisted of the 33 exoproteins identified in the biofilm matrix 387 produced by S. aureus 15981 strain and was referred as BME. 388 389 Transcriptional analysis of genes coding for biofilm matrix exoproteins. 390
Previous studies with several bacteria have shown that gene expression and protein 391 production differ when bacteria are grown under biofilm conditions in comparison with 392 planktonic growth (6-9). Therefore, we proceeded to investigate whether genes coding 393 for the biofilm matrix exoproteins identified with the proteomic analysis were 394 differentially expressed in biofilm conditions with respect to planktonic growth. 395
Transcriptome analyses revealed that S. aureus 15981 cells grown under biofilm 396 conditions expressed a markedly different repertoire of genes in comparison to their 397 planktonic counterparts. In total, we observed that 626 genes were differentially 398 expressed under biofilm growing conditions. From these, 276 genes were expressed in 399 higher amounts in biofilm cells, whilst 350 genes were down-regulated under biofilm 400 conditions. Then, we focused on expression levels of the genes coding for the BME 401 previously identified and found that expression of more than half of the identified 402 proteins (58%) was up-regulated under biofilm growing conditions (Table 2) . In order to investigate whether this multivalent extract might be able to induce a 410 protective immune response against S. aureus, we firstly evaluated the antibody 411 response in mice immunized with BME. For that, groups of 8 mice were immunized 412 with BME. Blood and sera samples were obtained at day 0 and 21 post immunization 413 and serum IgG and IgM levels were determined by ELISA. Results showed that 414 immunoglobulin levels were significantly higher in sera from mice immunized with 415 BME than in sera from control mice ( Figure 1A) . 416
Next, BME were separated in a SDS-PAGE gel (Fig. 1B) and interrogated with a pool 417 of sera obtained either from immunized or control mice. Results showed that the 418 majority of the biofilm matrix exoproteins were recognized by sera from immunized 419 mice while only a slight cross-reaction, probably caused by the presence of Protein A, 420 was observed when sera pool from control mice was used ( Figure 1B) . Also, because 421 BME contains a group of proteins that are equally expressed under biofilm or 422
planktonic growth conditions, we tested immune and control sera against an extract 423 containing extracellular proteins secreted by S. aureus cells grown planktonically 424 (PLKE). As expected, immune serum recognized part of the proteins present in the 425 planktonic extract ( Figure 1C) . 426
Finally, with the aim of analyzing if antibodies raised against the BME extract 427 recognized the biofilm formed by different S. aureus strains we isolated biofilm matrix 428 exoproteins from biofilms formed by several S. aureus strains and these were 429 interrogated with immune and control sera. In particular, we tested S. aureus 132 strain 430 (PNAG and FnBPs mediated biofilms), V329 and Newman::Bap strains (Bap 431 dependent biofilms) and ISP479 and 12313 strains (PNAG mediated biofilms). As it is 432 shown in figure 1D , immune sera against the BME extract recognized many proteins 433 present in all extracts analyzed. 434
Taken together, these data showed that BME was able to induce a humoral immune 435 response and that many of the proteins present in the extract contributed to this 436 immunogenicity. Also, antibodies generated against BME were capable of targeting a 437 broad range of biofilm matrices, suggesting that this multivalent extract might be 438 effective against a large number of relevant biofilm producing strains. 439
440
Antibodies against BME induce opsonophagocytic killing of S. aureus. 441
The presence of IgG and IgM in the immune serum can be correlated with high opsonic 442 activity (55). Thus, our next objective was to evaluate whether hyperimmune serum 443 obtained against BME promoted opsonophagocytic killing of S. aureus. S. aureus 132 444 strain grown under planktonic or biofilm conditions was pre-incubated with preimmune 445 serum, 1% or 10% of BME specific sera or PBS as control. After incubation, bacteria 446 were mixed with whole blood for 30 min (45). Staphylococcal killing was monitored 447 by spreading sample aliquots on TSA agar medium followed by colony formation and 448 enumeration. Results showed that antibodies against BME significantly induced 449 opsonophagocytic killing of both planktonic and sessile S. aureus cells (Figure 2) . 450
Additionally, data showed that killing of biofilm S. aureus cells was slightly higher 451 than killing of planktonic cells. 452 453 BME induces the production of IL-10 and IL-17 in ex-vivo stimulated splenocytes. 454 We next sought to characterize the cellular response stimulated by BME. For that, 455 cytokines production was examined after ex-vivo splenocyte stimulation with BME as 456 described in the materials and methods section. Supernatants of stimulated cells were 457 analyzed for the production of IFN-γ and IL-2 (prototypes Th1 cytokines), IL-10 458 (prototype Th2 cytokines) and Th17-associated cytokine IL-17. When production of 459 IL-17 was analyzed over time, a 10 fold increase was observed at the early time of 24 460 hours post-stimulation, when supernatants of splenocytes coming from mice 461 immunized with the BME extract where compared to supernatants of control mice 462 splenocytes. This difference increased to 50 fold at 96 hours post-stimulation (Figure  463 3). It is important to note that levels of IL-17 over time were barely detectable in 464 supernatants of control mice splenocytes (Figure 3) . With respect to cytokine IL-10, an 465 approximately 2.5 fold increase was observed at 24 hours post-stimulation that was 466 maintained over time (P<0.05) (Figure 3) . Lastly, mice immunization with BME led to 467 neither stimulation of cytokine IL-2 production nor induction of IFN-γ (Figure 3) . 468
Taken together, these results showed that immunization with BME induced a cellular 469 response characterized by production of cytokines IL-17 and IL-10. 470
471
Immunization with BME reduced biofilm formation in a mesh-biofilm model. 472 We next hypothesized whether immunization with BME might reduce the number of 473 bacterial cells inside a biofilm formed in-vivo. To analyze this hypothesis, we 474 compared the efficiency of BME in a mesh-biofilm model with the protective effect of 475 an extract containing the secreted proteins of S. aureus 15981 grown planktonically 476 (PLKE) and also, of a heat extract obtained from S. aureus 15981 (HE). Mice were 477 immunized at an interval of two weeks with 10 µg and 5 µg of the BME, PLKE, 10 8 478 heat-killed bacteria (HE) or with adjuvant alone. After immunization, sera from 479 immunized mice were extracted and were interrogated against the BME proteins. 480
Results showed that sera from mice immunized with PLKE and HE recognized fewer 481 proteins of the BME extract than sera from BME immunized mice ( Figure 4B) . 482
Seven days after the second immunization, polypropylene meshes coated with 10 4 CFU 483 of the biofilm forming strain S. aureus 132 were implanted in the intraperitoneal cavity 484 of immunized and control mice. After five days, all animals were sacrificed and meshes 485 were extracted. When the abdominal cavity of mice was opened, abdominal wall 486 adhesions were observed in all animals. Meshes removed from non-vaccinated mice 487 (control) were more difficult to extract from the abdominal cavity than meshes from 488 vaccinated mice. Also, as it is shown in figure 4C , meshes from control mice were 489 surrounded by purulent and necrotic tissue, whilst a healthier and a more vascularized 490 tissue surrounded the meshes coming from immunized mice. When the number of 491 bacteria on meshes was determined, results showed that immunization with BME 492 significantly reduced the number of bacteria attached to the polypropylene meshes 493 (P≤0.05) ( Figure 4A ). In contrast, immunization with PLKE or HE showed a slight but 494 not statistically significant reduction of the number of bacteria in the mesh-biofilm 495 model ( Figure 4A ). 496
Finally, we decided to investigate whether BME vaccinated mice were additionally 497 protected against bacterial population that propagates via detachment from the biofilm. 498
To do so, mesh-surrounding tissue, kidneys and liver from BME immunized mice were 499 extracted and bacterial colonization was determined. In contrast to the non-vaccinated 500 group (control), mice immunized with BME presented a significantly reduced number 501 of bacteria in liver and mesh-surrounding tissue (P≤0.05) ( Figure 4D ). Although there 502 was also a slight reduction in kidney colonization in immunized mice, differences 503 between control and vaccinated mice were not statistically significant (P=0.06) (Figure 504 Numerous evidence have demonstrated that S. aureus is able to produce 547 polysaccharidic and proteinaceous biofilm matrices (11-16). Therefore potential 548 antigens against S. aureus biofilm infections should be expressed by strains that form 549 either type of biofilm matrix. Our results showed that BME extracted from 550 exopolysaccharidic matrices of two unrelated clinical strains (S. aureus 15981 and 132) 551 comprised a high number of proteins in common. Moreover, all proteins except one 552 present in the BME isolated from a proteinaceous matrix produced by S. aureus 132 553
were also contained in PNAG-dependent matrices (Table 2) . Also, it is important to 554 note that 85% of exoproteins encompassed in the BME of S. aureus 15981 are identical 555 to the first S. aureus biofilm exoproteome identified and produced by the nasal carrier 556 strain S. aureus D30 (50). Accordingly, here we showed that antibodies raised against 557 an extract coming from a PNAG-dependent biofilm formed by strain 15981 recognized 558 many proteins from biofilms of different nature produced by different S. aureus strains 559 ( Figure 1D ). These data might explain why immunization with a BME extract obtained 560 whereas, other biofilm areas that do not express the vaccinated antigen will probably 567 persist. Hence, BME extract comprising most exoproteins of the biofilm matrix may 568 ensure that not only different areas of the biofilm but also various cell types present 569 within the biofilm are targeted. It is important to note that vaccination with other 570 multicomponent extracts such as a heat-killed or a PLKE extract, which have been 571
shown to provide protection against S. aureus infections (41, 61, 62), were less efficient 572 than BME to reduce the number of bacteria inside a biofilm, using a mesh associated 573 biofilm infection model. The reason behind the low efficiency of heat-killed and PLKE 574 extracts might be that they probably do not enclose biofilm specific antigens as the 575 BME extract (Figure 4) . Additional experimentation will be required to arrive at a 576 detailed picture of the localization of BME proteins into the biofilm structure. 577
Biofilm formation is a dynamic process that occurs through sequential steps in which 578 the initial attachment of planktonic bacteria to a surface is followed by their subsequent 579 proliferation and accumulation in multilayer cell clusters where bacteria are enclosed in 580 a self-produced polymeric matrix. As biofilm ages, bacterial cells escape from the 581 matrix and return to a planktonic existence, being able to reach other locations in the 582 host. This step represents a potentially important mechanism for the dissemination of 583 bacteria during infection. Our proteomic, transcriptomic and immunological analysis 584
showed that BME extract contains antigens that S. aureus produces under both 585 planktonic and biofilm growing conditions ( Table 2) . As a consequence, sera from 586 BME immunized mice recognized several proteins in the exoproteome extract of 587 planktonic bacteria (Fig. 1C) . Accordingly, mice immunized with this extract not only 588
showed a reduction in the number of bacteria inside a S. aureus biofilm but also 589 moderated tissue and organ colonization by bacteria that were released through 590 detachment from the biofilm. Nevertheless, clearance of the infection would likely 591 require an added antimicrobial treatment as it has been already proposed by Brady et al 592 (37) . 593
With respect to the immune response mounted after mice immunization with BME, 594 results showed an increase in the production of total immunoglobulins. The primary 595 antibodies function in the protection against S. aureus infections is neutralization and 596 opsonization of bacteria for phagocytosis. Although reduction in the number of biofilm 597 bacteria on PS-meshes in the opsonophagocyitc experiment could be due to both 598 neutralization and the opsonic activity of antibodies, we did not observe a significant 599 direct effect of BME-antibodies on S. aureus biofilms in vitro, in the absence of 600 immune system components (Supplementary Figure 1) . Hence, BME-antibodies seem 601 to protect against S. aureus infections likely through an increase in opsonization. 602
Importantly, these opsonic antibodies may help in the phagocytosis of bacteria inside a 603 biofilm that otherwise would be inaccessible due to the extracellular matrix coating. 604
Although antibodies unquestionably play an important role in the protection against S. 605 aureus infections, they may not be decisive for vaccine protective efficacy since 606 animals and humans have enough circulating antibodies to S. aureus (56, 63, 64) . The release of inflammatory cytokines by Th17 cells provokes the recruitment and 619 activation of neutrophils and might aid to devitalize the biofilm surface helping to 620 bacterial clearance. In the case of BME extract immunization, it did not only induce a 621 humoral response but also stimulated the production of IL-17 that might help to clear 622 bacteria in the biofilm. In order to elucidate the role of the induction of IL-17 by BME 623 administration in the efficiency of this multicomponent extract, we have performed a 624 preliminary experiment in which IL-17 cytokine was neutralized by administration of 625 an antibody against IL-17. BME-immunized mice that had been administered the 626 neutralizing antibody to IL-17 showed non-significant reduction in the number of 627 bacteria recovered from biofilm-infected meshes when compared with control BME-628 immunized mice (Supplementary Figure 2) . These preliminary results suggest a 629 putative role of IL-17 cytokine in the immune response against a S. aureus biofilm 630 related infection. BME immunized mice presented also significantly higher levels of 631 IL-10 compared to non-vaccinated mice. IL-10 cytokine has been shown to protect the 632 host from staphylococcal enterotoxin, endotoxin and septic shock (71-73). 633 
